Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 3
Submit an article Journal homepage
91
Views
16
CrossRef citations to date
0
Altmetric
Review

Advances in anti-obesity therapeutics

Tung M Fong Department of Metabolic Disorders, Merck Research Laboratories, R80M-213, PO Box 2000, Rahway, NJ 07065, USA. [email protected]
Pages 243-250 | Published online: 22 Apr 2005

Bibliography

  • GLAZER G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch. Intern. Med. (2001) 161:1814–1824.
  • ••Efficacy comparison of existing anti-obesity drugs.
  • HALPERN A, MANCINI MC: Treatment of obesity: an update on anti-obesity medications. Obes. Rev (2003) 4:25–42.
  • ••Efficacy comparison of existing anti-obesity drugs.
  • FARRIGAN C, PANG K: Obesity market overview. Nat. Rev Drug Discov. (2002) 1:257–258.
  • BARSH GS, SCHWARTZ MW: Genetic approaches to studying energy balance: Perception and integration. Nat. Rev Genet. (2002) 3:589–600.
  • FRIEDMAN JM: Modern science versus the stigma of obesity. Nat. Med. (2004) 10:563–569.
  • CONE RD, COWLEY MA, BUTLER AA et al.: The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int. J. Obes. Relat. Metab. Disord. (2001) 25\(Suppl. 5):563–567.
  • SMITH GP: Dopamine and food reward. Frog. Psychobiol Physic] Psycho] (1995) 16:83–144.
  • SCHULTZ W: Getting formal with dopamine and reward. Neuron (2002) 36:241–263.
  • SCISLOWSKI PW, TOZZO E, ZHANG Y et al: Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in obiob mice treated with dopaminergic agonists. Int. J. Obes. Relat. Metab. Disord. (1999) 23:425–431.
  • GOLDMAN-RAKIC PS, MULY ECR, WILLIAMS GV: D1 receptors in prefrontal cells and circuits. Brain Res. Rev. (2000) 31:295–301.
  • VAN REE JM, NIESINK RJ, VAN WOLFSWINKEL L et al.: Endogenous opioids and reward. Eur. Pharmacol (2000) 405:89–101.
  • GARDNER EL, VOREL SR: Cannabinoid transmission and reward-related events. Neurobiol Dis. (1998) 5:502–533.
  • BERRY EM, MECHOULAM R: Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther. (2002) 95:185–190.
  • BREIVOGEL CS, CHILDERS SR: The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. (1998) 5:417–431.
  • KISHI T, ASCHKENASI CJ, LEE CE et al: Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol (2003) 457:213–235.
  • PECKYS D, LANDWEHRMEYER GB: Expression of 14-, lc-, and 8-opioid receptor messenger RNA in the human CNS: a 33P in situ hybridisation study. Neuroscience (1999) 88:1093–1135.
  • WIRTSHAFTER D, DAVID JD: Set points, settling points and the control of body weight. Physic] Behav. (1977) 19:75–78.
  • •An early review on the theory of body weight control.
  • BERRIDGE KC: Motivation concepts in behavioral neuroscience. Physic] Behav. (2004) 81:179–209.
  • ••Review on motivational aspects of feedingcontrol.
  • BERTHOUD HR: Multiple neural systems controlling food intake and body weight. Neurosci. Biobehav. Rev (2002) 26:393-428. Review on redundancy of feeding control.
  • HAGAN MM, RUSHING PA, BENOIT SC, WOODS SC, SEELEY RJ: Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am. Physiol Regul Integr. Comp. Physic] (2001) 280:R814–R821.
  • OLSZEWSKI PK, WIRTH MM, GRACE MK, LEVINE AS, GIRAUDO SQ: Evidence of interactions between melanocortin and opioid systems in regulation of feeding. Neuroreport (2001) 12:1727–1730.
  • ALVARO JD, TATRO JB, QUILLAN JM et al.: Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol. Pharmacol (1996) 50:583–591.
  • DRYDEN S, FRANKISH H, WANG Q, WILLIAMS G: Neuropeptide Y and energy balance: one way ahead for the treatment of obesity? Eur.j Clin. Invest. (1994) 24:293–308.
  • HEISLER LK, COWLEY MA, TECOTT LH et al: Activation of central melanocortin pathways by fenfluramine. Science (2002) 297:609–611.
  • WADDEN TA, BERKOWITZ RI, WOMBLE LG et al: Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes. Res. (2000) 8:431–437.
  • ARNONE M, MARUANI J, CHAPERON F et al: Selective inhibition of sucrose and ethanol intake by SR-141716, an antagonist of central cannabinoid (CBI) receptors. Psychopharmacology (1997) 132:104–106.
  • SIMIAD J, KEANE M, KEANE PE, SOUBRIE P: SR-141716, a CBI cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179–181.
  • COLOMBO G, AGABIO R, DIAZ G et al.: Appetite suppression and weight loss after the cannabinoid antagonist SR-141716. Life Sci. (1998) 63:113–117.
  • VERTY AN, McGREGOR IS, MALLET PE: Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci. Lett. (2004) 354:217–220.
  • PERIO A, BARNOUIN MC, PONCELET M, SOUBRIE P: Activity of SR-141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. Behav. Pharmacol. (2001) 12:641–645.
  • DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomised controlled trial. JAMA (1999) 281:235–242.
  • JAMES WP, ASTRUP A, FINER N et al:Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2000) 356:2119–2125.
  • BATKAI S, PACHER P, OSEI-HYIAMAN D et al.: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 110: 1996-2002.
  • RANDALL MD, KENDALL DA, O'SULLIVAN S: The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. (2004) 142:20–26.
  • MENDIZABAL VE, ADLER- GRASCHINSKY E: Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. Curr. Vasc. Pharmacol. (2003) 1:301–313.
  • BATKAI S, PACHER P, JARAI Z, WAGNER JA, KUNOS G: Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CBI or CB2 receptors. Am..]: Physiol. Heart Circ. Physiol. (2004) 287(2):H595–H600.
  • SLEEMAN MW, ANDERSON KD, LAMBERT PD, YANCOPOULOS GD, WIEGAND SJ: The ciliary neurotropic factor and its receptor, CNTFR a. Pharm. Acta Hely. (2000) 74:265–272.
  • STAHL N, YANCOPOULOS GD: The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines. Neurobiol. (1994) 25:1454–1466.
  • GLOAGUEN I, COSTA P, DEMARTIS A et al.: Ciliary neurotropic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sri. USA (1997) 94:6456–6461.
  • LAMBERT PD, ANDERSON KD, SLEEMAN MW et al.: Ciliary neurotropic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Li. USA (2001) 98:4652–4657.
  • MARSH DJ, HOLLOPETER G, HUSZAR D et al.: Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genet. (1999) 21:119–122.
  • ZIOTOPOULOU M, ERANI DM, HILEMAN SM, BJORBAEK C, MANTZOROS CS: Unlike leptin, ciliary neurotropic factor does not reverse the starvation-induced changes of serum corticosterone and hypothalamic neuropeptide levels but induces expression of hypothalamic inhibitors of leptin signaling. Diabetes (2000) 49:1890–1896.
  • XU B, DUBE MG, KALRA PS et al: Anorectic effects of the cytokine, ciliary neurotropic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. Endocrinology (1998) 139:466–473.
  • ROWLAND NE, MARSHALL M, ROTH JD: Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats. Psychopharmacology (2000) 149:77–83.
  • GEHLERT DR, DRESHFIELD L, TINSLEY F et al: The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding. J. Pharmacol. Exp. Ther. (1998) 287:122–127.
  • ANDERSON JW, GREENWAY FL, FUJIOKA K et al: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. (2002) 10:633–641.
  • RITTER RC, COVASA M, MATSON CA:Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides (1999) 33:387–399.
  • REIDELBERGER RD, HERNANDEZ J, FRITZSCH B, HULCE M: Abdominal vagal mediation of the satiety effects of CCK in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 286:R1005–R1012.
  • MATSON CA, RITTER RC: Long-termCCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am. J. Physiol. (1999) 276:R1038–R1045.
  • BICKEL M, GOSSEL M, GEISEN K et al: Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats. Int. J. Obes. Relat. Metab. Disord. (2004) 28:211–221.
  • McCALLUM RW, SOYKAN I, SRIDHAR KR et al.: 8-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment. Pharmacol. Ther. (1999) 13:77–80.
  • ISHIGUCHI T, AMANO T, MATSUBAYASHI H et al: Centrally administered neuropeptide Y delays gastric emptying via Y2 receptors in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281:R1522–R1530.
  • MOLLER DM, KAUFMAN KD: Metabolic syndrome - a clinical and molecular perspective. Ann. Rev Med. (2005) 56:45–62.
  • FONG TM: Targeting metabolic syndrome. Expert Opin. Investig. Drugs (2004) 13:1203–1206.
  • VAN DER PLOEG LH: Obesity: an epidemic in need of therapeutics. Curr. Opin. Chem. Biol. (2000) 4:452–460.
  • SPANSWICK D, LEE K: Emerging antiobesity drugs. Expert Opin. Emerg. Drugs (2003) 8:217–237.
  • FAROOQI IS, KEOGH JM, YEO GS et al: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Eng]. I Med. (2003) 348:1085–1095.
  • HUSZAR D, LYNCH CA, FAIR-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131–141.
  • VAN DER PLOEG LHT, MARTIN WJ, HOWARD AD et al.: A role for the melanocortin 4 receptor in sexual function. Proc. Nati Acad. Sci. USA (2002) 99:11381–11386.
  • GANTZ I, FONG TM: The melanocortin system. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E468–E474.
  • LINDBLOM J, KASK A, HAGG E et al: Chronic infusion of a melanocortin receptor agonist modulates dopamine receptor binding in the rat brain. Pharmacol. Res. (2002) 45:119–124.
  • CABEZA DE VACA S, KIM G, CARR KD: The melanocortin receptor agonist MTII augments the rewatding effect of amphetamine in ad-libitum-fed and food-restricted rats. Psychopharmacology (2002) 161:77–85.
  • SEBHAT I, YE Z, BEDNAREK M et al: Melanocortin-4 receptor agonists and antagonists: chemistry and potential therapeutic utilities. Ann. Rep. Med. Chem. (2003) 38:31–40.
  • SAILER AW, SANO H, ZENG Z et al: Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc. Nati Acad. Sci. USA (2001) 98:7564–7569.
  • SAITO Y, NOTHACKER HP, WANG Z et al.: Molecular characterization of the melanin-concentrating-hormone receptor. Nature (1999) 400:265–269.
  • SHIMADA M, TRITOS NA, LOWELL BB, FLIER JS, MARATOS-FLIER E: Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature (1998) 396:670–674.
  • MARSH DJ, WEINGARTH DT, NOVI DE et al.: Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. USA (2002) 99:3240–3245.
  • CHEN Y, HU C, HSU CK et al: Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology (2002) 143:2469–2477.
  • KOWALSKI TJ, McBRIAR MD: Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs (2004) 13:1113–1122.
  • SHAW WN: Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacol Biochem. Behav. (1993) 46:653–659.
  • GLASS M, BILLINGTON CJ, LEVINE AS: Opioids and food intake: distributed functional neural pathways? Neuropeptides (1999) 33:360–368.
  • STATNICK MA, TINSLEY FC, EASTWOOD BJ et al.: Peptides that regulate food intake: antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization. Am. I Physiol Regul Integr. Comp. Physiol (2003) 284:R1399–R1408.
  • BODNAR RJ: Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides (2004) 25:697–725.
  • DREWNOWSKI A: Metabolic determinants of binge eating. Addictive Behav. (1995) 20:733–745.
  • DE ZWAAN M, MITCHELL JE: Opiate antagonists and eating behaviour in humans: a review. J. Clin. Pharmacol (1992) 32:1060–1072.
  • KIM S, WAGNER HN, VILLEMAGNE VL et al.: Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. I Nuc. Med. (1997) 38:1726–1731.
  • CHEN RZ, HUANG RR, SHEN CP, MACNEIL DJ, FONG TM: Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. Eur. Pharmacol (2004) 495:63–66.
  • HAWKINS MF, CUBIC B, BAUMEISTER AA, BARTON C: Microinjection of opioid antagonists into the substantia nigra reduces stress-induced eating in rats. Brain Res. (1992) 584:261–265.
  • BRUGMAN S, CLEGG DJ, WOODS SC, SEELEY RJ: Combined blockade of both µ-and x-opioid receptors prevents the acute orexigenic action of agouti-related protein. Endocrinology (2002) 143:4265–4270.
  • SETOLA V, HUFEISEN SJ, GRANDE-ALLEN KJ et al: 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol (2003) 63:1223–1229.
  • LEIBEL RL, ROSENBAUM M, HIRSCH J: Changes in energy expenditure resulting from altered body weight. N Engl. J. Med. (1995) 332:621–628.
  • ••Pivotal study demonstrating thecompensatory reduction of metabolic rate in response to dieting.

Websites

  • http://www.theheart.org Website for highlights from the ACC 2004, ESC 2004 and AHA 2004 scientific sessions.
  • http://www.regeneron.com REGENERON-PHARMACEUTICALS: Press release.
  • http://www.iddb3.com Database for investigational drugs.
  • http://www.alizyme.com ALIZYME.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.